Consolidated Statements of Cash Flows - USD ($) $ in Thousands		12 Months Ended
		Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
Cash flows provided by (used in) operating activities
Net income (loss)		$ 3,620,127	$ (1,159,816)	$ (103,440)
Adjustments to reconcile net income (loss) to net cash provided by (used in) operating activities
Amortization, accretion and depreciation		(134,753)	(26,950)	(20,989)
Equity in undistributed (earnings) losses of other ventures		(7,642)	10,723	13,200
Net realized and unrealized (gains) losses on investments		(482,794)	1,635,192	205,897
Change in:
Premiums receivable		(126,852)	(1,357,929)	(886,911)
Prepaid reinsurance premiums		223,385	(166,690)	(31,140)
Reinsurance recoverable		663,909	(442,256)	(1,342,659)
Deferred acquisition costs and value of business acquired		37,301	(322,578)	(215,639)
Reserve for claims and claim expenses		(34,656)	2,597,943	2,913,492
Unearned premiums		(227,001)	1,027,894	767,614
Reinsurance balances payable		(1,040,110)	67,318	372,611
Other		(579,280)	(259,168)	(437,221)
Net cash provided by (used in) operating activities		1,911,634	1,603,683	1,234,815
Cash flows provided by (used in) investing activities
Proceeds from sales and maturities of fixed maturity investments trading		21,796,577	22,086,168	15,543,565
Purchases of fixed maturity investments trading		(24,771,411)	(24,923,131)	(15,680,351)
Net sales (purchases) of equity investments		564,325	(202,309)	206,595
Net sales (purchases) of short term investments		1,843,180	640,411	(252,833)
Net sales (purchases) of other investments		(801,850)	(618,790)	(617,782)
Net sales (purchases) of investments in other ventures		(25,265)	(773)	(23,835)
Return of investment from investment in other ventures		5,554	2,248	8,345
Net purchase of Validus		(2,433,746)	0	0
Net cash provided by (used in) investing activities		(3,822,636)	(3,016,176)	(816,296)
Cash flows provided by (used in) financing activities
Dividends paid – RenaissanceRe common shares		(75,112)	(64,675)	(67,828)
Dividends paid – preference shares		(35,375)	(35,396)	(32,889)
RenaissanceRe common share repurchases		0	(166,664)	(1,027,505)
RenaissanceRe common share issuance		1,351,608	0	0
Issuance of debt, net of expenses		740,581	0	0
Repayment of Medici Revolving Credit Facility		(30,000)	0	0
Drawdown of Medici Revolving Credit Facility		75,000	0	30,000
Redemption of preference shares		0	0	(275,000)
Issuance of preference shares, net of expenses		0	0	488,653
Net third-party redeemable noncontrolling interest share transactions		582,455	1,002,988	594,279
Taxes paid on withholding shares		(20,518)	(10,911)	(12,171)
Net cash provided by (used in) financing activities		2,588,639	725,342	(302,461)
Effect of exchange rate changes on foreign currency cash		5,542	22,471	6,148
Net increase (decrease) in cash and cash equivalents		683,179	(664,680)	122,206
Cash and cash equivalents, beginning of year		1,194,339	1,859,019	1,736,813
Cash and cash equivalents, end of year		1,877,518	1,194,339	1,859,019
Supplemental disclosure of cash flow information
Income taxes paid (refunded)		26,777	3,129	(4,261)
Interest paid		73,543	46,247	21,172
Non-cash consideration	[1]	$ 285,168	$ 0	$ 0

[1] Represents the non-cash component of the total Validus acquisition consideration. Refer to "Note 3. Acquisition of Validus” for additional information related to the Validus Acquisition.